述评：重新考虑药品研发投资。
Commentary: Reconsidering Pharmaceutical Research and Development Investments.
机构信息
Associate Professor, School of Public Policy and Administration, Carleton University, Ottawa, ON.
出版信息
Healthc Policy. 2023 Feb;18(3):25-30. doi: 10.12927/hcpol.2023.27037.
Following Lee and colleagues' (2023) article explaining how Canadians are being shortchanged by drug companies when it comes to investments in research and development (R&D), this rejoinder adds context and appends two other very problematic elements in the debate between wishful narratives over the industry's contribution in R&D and actual numbers. First, even the current stricter definition of R&D investment might simply be too large considering that elements such as seeding trials - a well-known marketing device - can be accounted for as R&D expenditures. Second, this rejoinder identifies how Statistics Canada acted in concert with Innovative Medicines Canada to reinforce the industry's preferred narratives around R&D expenditures. This situation puts into question the trustworthiness of Canada's statistical agency.
继李和他的同事（2023 年）发表的文章解释了加拿大在药品研发投资方面如何被制药公司亏待之后，这篇反驳文章增加了背景信息，并补充了关于行业在研发方面的贡献的一厢情愿的说法与实际数据之间争论的另外两个非常有问题的因素。首先，即使是目前更严格的研发投资定义也可能太大了，因为像种子试验这样的元素——一种众所周知的营销手段——可以算作研发支出。其次，这篇反驳文章指出了加拿大统计局如何与创新药物加拿大合作，以加强行业对研发支出的偏好叙事。这种情况使得加拿大统计机构的可信度受到质疑。
Zotero 插件